Search Results for: PULMONARY DELIVERY Pulmonary Delivery of
Articles
2022 Respiratory Drug Development eBook - Demand Accelerates Devices July 8, 2022
This fourth annual Drug Development & Delivery Respiratory eBook highlights the pMDI development path, as well as the importance of a holistic approach to that development that includes the patient and all stakeholders across the product’s life cycle.
MERXIN & Gerresheimer Worked Successfully Together to Realize the Shortest Possible Time to Market for the MERXIN MRX003 Capsule DPI June 14, 2022
Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN...Lonza Announces Expansion of Inhalation Capabilities at US Facility May 23, 2022
Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, recently announced it will invest in additional inhalation...Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products March 31, 2022
Lonza recently announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza...Owen Mumford & Noble International Announce Collaboration March 29, 2022
Owen Mumford Pharmaceutical Services recently announces its alliance with Noble International, an Aptar Pharma company and world leader in providing drug delivery….
Viatris Announces Receipt of First FDA Approval for Generic Version of Symbicort Inhalation Aerosol in Partnership With Kindeva March 16, 2022
Viatris Inc. and Kindeva Drug Delivery L.P. recently announced Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the US FDA...Catalent & TFF Pharmaceuticals Announce New Inhalation Dry Powder Development & Manufacturing Agreement March 1, 2022
Catalent and TFF Pharmaceuticals, Inc. recently announced their collaboration agreement focused on the generation, testing, and manufacture of dry powder...TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2 February 24, 2022
TFF Pharmaceuticals, Inc. recently announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the company’s inhaled niclosamide product candidate completely….
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program January 27, 2022
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
TFF Pharmaceuticals Announces Final Data From Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients December 21, 2021
TFF Pharmaceuticals, Inc. recently announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients….
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients November 8, 2021
TFF Pharmaceuticals, Inc. recently announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF...Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop & Promote High Payload Dry Powder Inhaler August 17, 2021
Aptar Pharma recently announced it has entered into an agreement with Pharmaxis under which Aptar Pharma has the option to acquire the worldwide rights to….
DisperSol & Catalent Collaborate to Establish KinetiSol Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline August 4, 2021
DisperSol Technologies and Catalent recently announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products…..
Noble Further Expands Capabilities of Its New Human Factors + Program June 9, 2021
In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….
Vectura & Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19 May 6, 2021
Vectura Group plc and Inspira Pharmaceuticals Limited recently announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the potential treatment of….
DRY-POWDER THERAPEUTICS - Respiration Inspiration: Local Treatment of Lung Cancer by Dry-Powder Inhaler May 3, 2021
Philip Kuehl, PhD, and Kimberly B. Shepard, PhD, describe the formulation and manufacturing considerations for development of dry-powder therapeutics for local treatment of lung cancer. Two case studies are presented in which two approved drugs are successfully formulated for DPI administration to the lung.
PRODUCT DEVELOPMENT STRATEGY - ESCP, Estimating Product Performance Part 2 – Choosing a Seesaw March 29, 2021
Josef Bossart, PhD, introduces, in a series of short articles, a qualitative model to help understand and visualize the potential of a product with prescribers, patients, and payors. This simple model can help weed out product ideas that may at first glance seem attractive but offer little potential in the real world.
Aptar Pharma & Noble Partner With dne pharma on its Nasal Naloxone Treatment March 17, 2021
Aptar Pharma and Noble, an Aptar Pharma company, recently announced their collaboration with dne pharma. Both companies are providing their nasal drug delivery….
Noble Launches Human Factors Engineering Services to Support Product Development and US FDA Approval of Medical Devices & Combination Products February 4, 2021
Noble, an Aptar Pharma company and world leader in providing drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, recently announced the launch of Human Factors Plus (HF+), an expanded service to further….